PDCD1LG2 and anal carcinoma: Uniquely for the tumor microenvironment, the higher expression of immune checkpoint biomarkers such as PD-1, PD-L2, LAG-3 and OX40L was observed in the clinically unfavorable cohort of recurrent anal cancer patients.